Drugs / ELX/TEZ/IVA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05882357 | Jun 2023 → Sep 2025 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-06-07 | Vertex Pharmaceuticals Incorporated | Results Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA® vrtx.com ↗
Data from a randomized, double-blind, Phase 3 study (abstract WS06.04) demonstrated that people with CF who have rare, non-F508del mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsive to TRIKAFTA® in vitro demonstrated clinical benefit from receiving TRIKAFTA®. |
| 2023-06-09 | Vertex Pharmaceuticals Incorporated | Results Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference vrtx.com ↗
The data on TRIKAFTA in particular demonstrate that this medicine improves lung function sustainably and in a real-world setting. |
| 2019-10-31 | Vertex Pharmaceuticals Incorporated | Results Phase 3 Results from Two Studies of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet vrtx.com ↗
Both studies met primary and all key secondary endpoints, demonstrating statistically significant and clinically meaningful improvements in lung function and other measures of disease. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-07 | Vertex Pharmaceuticals Incorporated | Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA® vrtx.com ↗ |
| 2023-06-09 | Vertex Pharmaceuticals Incorporated | Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference vrtx.com ↗ |
| 2019-10-31 | Vertex Pharmaceuticals Incorporated | Phase 3 Results from Two Studies of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet vrtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELX/TEZ/IVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05882357 ↗ |
| Route | Oral | “Fixed-dose combination granules for oral administration.” NCT05882357 ↗ |